Share this video  

SABCS 2022 | TAILORx: an update incl 12-year event rates in woman with ER+ lymph node-negative breast cancer

Joseph Sparano, MD, Icahn School of Medicine at Mount Sinai, New York, NY, shares an update on the Phase III TAILORx (NCT00310180) trial that included 10,273 woman with ER-positive, lymph node-negative breast cancer, and are candidates to receive adjuvant systemic chemotherapy in addition to endocrine therapy in order to reduce risk of recurrence. All patients had the 21-gene Oncotype DX Recurrence Score guiding their treatment. The study was designed to address where there was therapeutic equipoise. Patients who had a recurrence score of 11-25 were randomized to receive either chemotherapy plus endocrine therapy or endocrine therapy alone. The primary results reported 4 years ago revealed that endocrine monotherapy was non-inferior to chemotherapy plus endocrine therapy. The updated analysis with 3.5 years further follow-up showed that the primary results remain unchanged, and patients continued to exhibit a risk of recurrence beyond 5 years. Additionally, racial disparities were revealed between Black and White woman. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.